Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 7Recruiting 3Active not recruiting 3Withdrawn 2Unknown 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 8Breast Neoplasms 6Prostatic Neoplasms 5Triple Negative Breast Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Lung Neoplasms 2Glioma 2Glioblastoma 2Uterine Cervical Neoplasms 1Solid Tumor 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Neoplasm, Residual 1Metastatic Castration-sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1

Interventions

Paclitaxel 17Carboplatin 16Magnetic Resonance Spectroscopy 11Taxes 10Specimen Handling 10Bevacizumab 10olaparib 9Gemcitabine 9pembrolizumab 8Immunoglobulin G 7Disulfides 7Biopsy 7liposomal doxorubicin 6Doxorubicin 5cediranib 4Nivolumab 4Cyclophosphamide 4Cisplatin 4oregovomab 3niraparib 3adavosertib 3X-Rays 3Topotecan 3tremelimumab 2rucaparib 2mirvetuximab soravtansine 2berzosertib 2aldesleukin 2Surveys and Questionnaires 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Neoplasms × niraparib × Clear all
NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

CanariaBio Inc.

Phase 2 Active not recruiting
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
31 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

University of Washington

Phase 1 Active not recruiting
18 enrolled
BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡